Real-World Evidence. Delivered
Huma’s global, Class IIb regulated platform captures real-world data across multiple therapeutic areas and patient registries, which can be aggregated to provide valuable insights at an individual, patient cohort and population level.
Collect real-world, clinically meaningful data at scale across your operating markets for more accurate, complete outcomes reporting.
Improve clinical outcomes
adherence and retention rates across our care and research deployments are the result of high engagement rates1
Our platform can almost double clinical capacity and reduce readmission rates by >30%2
lower mortality amongst Huma patients compared with patients not using Huma3
of patients highlighted as deteriorating had operation dates brought forward4
Collect high-quality, real-world data at scale
Huma’s remote patient monitoring platform captures a broad range of digital biomarkers from ePRO, connected devices and wearables, ensuring higher accuracy with minimal human error. Our platform supports continuous data collection across local and global health ecosystems and patient registries, enabling the creation of aggregated datasets across multiple countries for more accurate, evidence-based conclusions.
With EU MDR Class IIb accreditation, Huma can support patients with higher acuity and risk profiles, ensuring that datasets and AI-based models are representative of the severity of illness encountered across health systems.
.png)
Collect high-quality, real-world data at scale
With EU MDR Class IIb accreditation, Huma can support patients with higher acuity and risk profiles, ensuring that datasets and AI-based models are representative of the severity of illness encountered across health systems.
A global, regulated platform that facilitates RWE reporting
Ready to deploy in 60+ countries, Huma enables real-world data collection and Real-World Evidence reporting from patients in your operating markets worldwide, including those in higher risk groups with multiple comorbidities.
Huma’s software as a medical device platform is certified under ISO 13485 and 27001 and Cyber Essentials Plus, is FDA 21 CFR (Part 11, 50 and 820 ff) and GxP compliant, and is registered EU MDR Class IIb with enforcement discretion for EU MDR Class IIb use cases.
A global, regulated platform that facilitates RWE reporting
Huma’s software as a medical device platform is certified under ISO 13485 and 27001 and Cyber Essentials Plus, is FDA 21 CFR (Part 11, 50 and 820 ff) and GxP compliant, and is registered EU MDR Class IIb with enforcement discretion for EU MDR Class IIb use cases.
Near real-time data collection across therapeutic areas and patient registries
With more than 450 unique deployments to date, our platform provides companion app solutions across diabetes, heart failure, cardiovascular disease, asthma, and many more therapeutic areas.
Capture broad datasets across health economies—including specific patient disease registries—with more complex, higher acuity patients.
Near real-time data collection across therapeutic areas and patient registries
Capture broad datasets across health economies—including specific patient disease registries—with more complex, higher acuity patients.
Regulatory, safety and compliance
MHRA registered Medical Device Class IIb
Part 11
Part 50
Part 820 ff
ISO 13485: 2016 certified (Medical Devices: Quality Management Systems)
ISO 27001: 2013 certified
Committed to GDPR compliance
NHS Registration on Data Security and Protection Toolkit
CyberEssentials / CyberEssentials Plus
Request a meeting
